A next-gen platform technology that disrupts the efficacy-toxicity trade-off with clinically-validated polymer-drug conjugates
Superior Therapeutic Index
Sagitta® drug delivery platforms are discovered to improve therapeutic index across a spectrum of payloads by combining active targeting with optimized pharmacokinetics, addressing one of oncology’s most persistent challenges:
The efficacy-toxicity trade-off.
SUPERIOR THERAPEUTIC INDEX
Sagitta® drug delivery platforms are discovered to improve therapeutic index across a spectrum of payloads by combining active targeting with optimized pharmacokinetics, addressing one of oncology’s most persistent challenges: The efficacy-toxicity trade-off.RS Research announces poster presentation at ASCO Annual Meeting 2025, Chicago
RS-0139 is a tumor-targeted prodrug designed to enhance the therapeutic index of docetaxel (DTX) by selectively delivering the active agent to tumor tissues. DTX is covalently bound to a polymer backbone, together with a targeting peptide, which shows a high affinity to αvβ3, αvβ5 and αvβ6 integrin receptors highly overexpressed on the tumor cell surface.
RS Research Co-Founder Prof. Rana Sanyal won the European Prize for Women Innovators
The EC announced the winners of the 10th edition of the European Prize for Women Innovators at the R&I Week opening in Brussels. The “Women Innovators” Prize in the leading category was awarded to RS Research Co-Founder Prof. Rana Sanyal for her successful work in the field of biotechnology.
RS Research was featured in the cover story of Forbes Türkiye
Being one of the success stories for translating scientific research to real-world therapeutic impact, RS Research’s accomplishments in targeted therapies were on the cover of Forbes Türkiye September 2025 issue.
